New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to include two new products, including Celgene's Reblozyl for treating transfusion-dependent anemia in adult patients with myelodysplastic syndromes or beta thalassemia. The list, which contains information dating back to January 2018, comprises brand name, generic name, company, therapeutic indication, date of marketing authorization and product type (eg, medicine, vaccine, biologic).
You may also be interested in...
Drug companies have their last chance to negotiate which documents and information Italy’s regulator, AIFA, will be entitled to request of them when they submit pricing and reimbursement applications.
This is an update of recommendations from the European Medicines Agency's Committee for Medicinal Products for Human Use on the authorization of new medicines in the European Union, and updates on EU marketing authorization changes recommended by the CHMP.
New medicines under evaluation at the European Medicines Agency.